A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

209

Participants

Timeline

Start Date

March 7, 2019

Primary Completion Date

May 27, 2022

Study Completion Date

May 27, 2022

Conditions
Postoperative Gastrointestinal Dysfunction
Interventions
DRUG

TAK-954 Placebo

TAK-954 placebo-matching intravenous infusion.

DRUG

TAK-954

TAK-954 intravenous infusion.

Trial Locations (25)

11794

Stony Brook University Hospital, Stony Brook

17033

Penn State Health Milton S. Hershey Medical Center, Hershey

20246

Universitaetsklinikum Hamburg-Eppendorf, Hamburg

30617

University of South Alabama Medical Center, Mobile

32804

Center for Colon & Rectal Surgery - Altamonte Springs, Orlando

33136

University of Miami Leonard M. Miller School of Medicine, Miami

33331

Cleveland Clinic Florida, Weston

40536

University of Kentucky, Lexington

43210

The Ohio State University Wexner Medical Center, Columbus

44111

Fairview Hospital, Cleveland

44791

Sankt Josef-Hospital, Bochum

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

68167

Universitatsklinikum Mannheim, Mannheim

70121

Ochsner Medical Center, New Orleans

77024

HD Research Corp., Houston

77089

North Star Medical, Houston

79106

Universitatsklinikum Freiburg, Freiburg im Breisgau

80045

University of Colorado, Aurora

81675

Klinikum Rechts der Isar der Technischen Universitat Munchen, München

90007

Keck School of Medicine, Los Angeles

90048

Cedars-Sinai Medical Center, Los Angeles

92504

Parkview Community Hospital Medical Center, Riverside

92868

University of California Irvine Medical Center, Orange

93053

Universitaetsklinikum Regensburg, Regensburg

01605

University of Massachusetts Memorial Medical Center, Worcester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

lead

Takeda

INDUSTRY